Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-08-13
2010-11-16
Andres, Janet L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S223200, C514S226500, C514S230500, C514S252130, C514S278000, C544S048000, C544S070000, C544S386000, C544S392000, C544S393000, C544S398000, C546S016000, C546S017000, C546S019000, C546S020000
Reexamination Certificate
active
07834008
ABSTRACT:
The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders.
REFERENCES:
patent: 4478836 (1984-10-01), Mouzin et al.
patent: 5434158 (1995-07-01), Shah et al.
patent: 0068999 (1983-01-01), None
patent: 0673928 (1995-09-01), None
patent: WO 97/10211 (1997-03-01), None
patent: WO 03/051869 (2003-06-01), None
Bonnaud, B. et al. (1987) “1-Aryl-2-(aminomethyl)cyclopropancarboxylic acid derivatives. A new series of potential antidepreassants”, Journal of Medicinal Chemistry; 30(2): 318-325.
Bjørnholm Berith
Hansen Tore
Kehler Jan
Nielsen Søren Møller
Nørgaard Morten Bang
Andres Janet L.
Buck Margaret M.
Covington Raymond
H. Lundbeck A/S
Johnson Mary C.
LandOfFree
Cyclopropyl derivatives as NK3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclopropyl derivatives as NK3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopropyl derivatives as NK3 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251430